Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 28;14(3):682. doi: 10.3390/cancers14030682

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(A) Kaplan–Meier estimate of RFS in cohort-1 and cohort-2. At time of analysis, after a median follow-up of 235 (43–287) weeks for cohort-1 and 190 (50–210) weeks for cohort-2, estimated 12-months RFS-rate was, respectively, 55.9% (95% CI, 39–72) and 85.7% (95% CI, 70–100). Median RFS for cohort-1 was 85 weeks (95%, CI 0–254), not-reached in cohort-2. (B) Kaplan–Meier estimate of DMFS in cohort-1 and cohort-2. At time of analysis, 12-months DMFS-rate was 76.5% (95% CI, 62–90) in cohort-1. No distant metastases occurred in cohort-2. Median DMFS has not been reached at time of analysis in either cohort. (C) Kaplan–Meier estimate of OS in cohort-1 and cohort-2. After a median follow-up of 208 (43–256) weeks for cohort-1 and 157 (78–182) weeks for cohort-2, estimated 12-months OS-rate was, respectively, 97.1% (95% CI, 91–102) and 100%. Median OS has not been reached at time of analysis in either cohort.